MedImmune is increasingly concentrating its workforce in Maryland, both through new hires and consolidations from California, as it prepares to take a host of midstage drug candidates through clinical trials.
The Gaithersburg biotech is entering a pivotal period. Its parent, British pharmaceutical giant AstraZeneca PLC, is laying off employees by the thousands at the same time that it is investing more heavily in its Maryland-based biologics arm.
{iframe}http://www.bizjournals.com/washington/print-edition/2012/09/14/after-growth-medimmune-pushes-on.html{/iframe}